Janssen Agrees With Creation Of Invokana MDL, Transfer To New Jersey

Mealey's (October 17, 2016, 12:40 PM EDT) -- WASHINGTON, D.C. — Janssen Pharmaceuticals Inc. on Oct. 12 said it agrees with some plaintiffs that at least 57 federal lawsuits alleging kidney failure or ketoacidosis from the diabetes drug Invokana should be centralized in a multidistrict litigation (In Re:  Invokana [Canagliflozin] Products Liability Litigation, MDL Docket No. 2750, JMPDL)....

Attached Documents

Related Sections